EGFR and non-small cell lung carcinoma: Depending on the cancer cell type and the presence or absence of a sensitizing EGFR mutation, gefitinib exhibited half-maximal inhibitory concentrations (IC50) ranging from submicromolar levels to 13 μM across various non-small cell lung cancer (NSCLC) cell lines [69].